AgomAb Therapeutics NV (AGMB) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($454.1 million vs $431.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | DMAC |
|---|---|---|
| Share price | $9.22 | $8.01 |
| Market cap | $454.07M | $431.94M |
| 1-day change | +4.77% | +0.25% |
| YTD return | — | +0.63% |
| 1-year return | — | +15.09% |
| 5-year return | — | +95.37% |
| EPS (TTM) | $-2.16 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $10.42 |
| 52-week low | $7.97 | $5.25 |
| Distance from 52-week high | -48.26% | -23.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.57% | +93.51% |
| Average volume | 139.21K | 177.22K |
| Shares outstanding | 49.25M | 53.93M |
| Employees | 62 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
AGMB vs DMAC FAQ
Which is bigger, AgomAb Therapeutics NV or DiaMedica Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $454.07M compared with $431.94M for DiaMedica Therapeutics (DMAC).
Are AgomAb Therapeutics NV and DiaMedica Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for DiaMedica Therapeutics.